ASCO 2022 Conference Coverage
ASCO 2022 Navitoclax + Ruxolitinib in JAKi-Naive Pts With MF: Preliminary Safety & Efficacy in a Multicenter, Open-Label Phase 2 Study
By
ASCO 2022 Conference Coverage
FEATURING
Francesco Passamonti
By
ASCO 2022 Conference Coverage
FEATURING
Francesco Passamonti
Login to view comments.
Click here to Login
